Key result
Pulmonary delivery of antiarrhythmic drugs such as flecainide and metoprolol is a promising strategy for rapid conversion of atrial fibrillation, demonstrating efficacy and safety in early studies.
Why the study?
Existing pill-in-the-pocket regimens for self-administered AF cardioversion have significant drawbacks, including a long latency of effects in the range of hours and the potential for hypotension and other adverse effects.
Does pulmonary delivery of antiarrhythmic drugs improve rapid conversion of new-onset atrial fibrillation?
Does pulmonary delivery of antiarrhythmic drugs improve rapid conversion of new-onset atrial fibrillation?
Pulmonary delivery of antiarrhythmic drugs offers a promising, rapid-acting strategy for the conversion of new-onset atrial fibrillation, potentially overcoming the delayed onset of traditional oral regimens.
No takes yet. Share an insight, caveat, or question.
May enable rapid AF conversion; hypothesis-generating preclinical findings require randomized human trials before any practice change.
Verrier et al. (2020) conducted a review in Atrial fibrillation. Pulmonary delivery of antiarrhythmic drugs (flecainide, metoprolol) was evaluated. Pulmonary delivery of antiarrhythmic drugs such as flecainide and metoprolol is a promising strategy for rapid conversion of atrial fibrillation, demonstrating efficacy and safety in early studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: